EICHORCondition: Stroke · Acute Stroke · Ischemic Stroke · Sponsor: Wellumio R&D Australia Pty Ltd
To assess the safety and feasibility of the Wellumio 'Axana' device in the hospital setting with healthy controls and patients.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: Healthy Participants: * Adults aged 18 years or older. * Able to undergo an in-hospital MRI scan. * Able to provide informed consent. * Head size considered suitable for scanning with the Wellumio Axana brain scanner. Hospital Patients: * Adults aged 18 years or older. * Presenting to hospital with an acute neurological deficit suspected to be stroke within 24 hours of symptom onset. * Clinical and radiological diagnosis of stroke, including ischemic stroke, haemorrhagic stroke, or subarachnoid haemorrhage. * Able to undergo an in-hospital MRI scan. * Up to 72 hours post-acute stroke. * Able to provide written informed consent or, where this is not possible, informed consent provided by a legally authorised representative. * Head size considered suitable for scanning with the Wellumio Axana brain scanner. Exclusion Criteria: General: * Pregnant or breastfeeding. * Contraindication to neuroimaging, including any condition that prohibits MRI. * Presence of an implanted electro-stimulating device in the head or neck. * Presence of a large metallic craniofacial implant, such as a bone fixation plate or mesh. Small metallic objects, such as aneurysm coils, are acceptable. * Presence of an intracranial pressure monitor or another similar sensor that may compromise placement of the investigational device. * Inability to wear the investigational device, including because of scalp skin lesions or previous intracranial surgery. * Unable to lie still for the duration of the scan. * Any other condition or symptom that, in the investigator's judgement, prevents participation in the study. * Unable to provide informed consent and, where applicable, consent cannot be obtained from a legally authorised representative. Healthy Participants: * History of a neurological condition, including brain tumour, previous stroke, or neurological trauma. * Post-study MRI findings indicating a brain condition associated with structural changes.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Royal Melbourne Hospital, also known as RMH Parkville | Melbourne, Victoria, Australia | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07751328